Corynebacterium spp. have emerged as opportunistic pathogens, with
increasing reports of isolation from patients with mild and severe
infections. Corynebacterial isolates were found expressing
multidrug-resistant (MDR) phenotypes in most cases. In the present work,
we report the isolation of an MDR C. glucuronolyticum strain from the
human urogenital tract. In addition, we provide comprehensive genomic
data of the isolate that was first identified by mass spectrometry
(MALDI-TOF) and had its antimicrobial susceptibility profile determined
by the disc diffusion method. Genomic analyses were applied to confirm
the species identification and predict genes involved in the virulence,
antimicrobial resistance, and CRISPR-Cas systems. C. glucuronolyticum
isolate exhibited resistance to benzylpenicillin, clindamycin, and
tetracycline. Two virulence (mprA and tlyC) and several antimicrobial
genes, including those related to tetracycline and lincosamides, were
found in the genome. Additionally, the Type I-E CRISPR-Cas system was
detected. Although C. glucuronolyticum has been isolated from patients
with human infections, mostly male patients with genitourinary tract
infections, its pathogenic potential is unclear. Presently, the clinical
resolution only occurred with antimicrobial treatment considering our
results, reinforcing that the antimicrobial susceptibility profile
should be performed in cases of infection caused by Corynebacterium
spp., especially in the face of the emergence of MDR isolates. Moreover,
our data revealed putative virulence and antimicrobial resistance
factors, which should be better characterized to understand the
pathogenicity potential of C. glucuronolyticum for the genitourinary
tract.